The Colgate-Palmolive Company (NYSE: CL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings provide detailed information on Colgate-Palmolive’s Oral Care, Personal Care, Home Care and Pet Nutrition businesses, its financial performance and its capital structure.
Colgate-Palmolive’s 8-K filings illustrate how the company uses SEC reports to communicate material events. For example, an 8-K dated November 10, 2025 describes the execution of an underwriting agreement and the issuance of €600,000,000 of 3.250% Senior Notes due 2035 under an automatic shelf registration statement. Other 8-Ks furnish quarterly earnings press releases and explain multi-year productivity initiatives, such as the Strategic Growth and Productivity Program designed to support the company’s 2030 strategy by aligning its organizational structure, optimizing its global supply chain and streamlining overhead.
Filings also list Colgate-Palmolive’s securities registered under Section 12(b) of the Exchange Act, including its common stock (ticker CL) and various series of notes traded on the New York Stock Exchange. Through proxy statements and other periodic reports, investors can review topics such as segment reporting, non-GAAP financial measures like Base Business and organic sales growth, and risk factor disclosures.
On Stock Titan, these SEC documents are updated from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in capital allocation, new debt offerings, productivity program charges or revisions to guidance. Users can quickly scan filings for material information while retaining access to the complete original documents for deeper analysis.
Colgate-Palmolive Chief People Officer Sally Massey sold 8,599 shares of Common Stock in an open-market transaction. The sale took place on May 7, 2026 at a weighted average price of $87.4093 per share, with individual prices ranging from $87.36 to $87.53.
After the sale, Massey directly owned 13,785 shares of Colgate-Palmolive common stock and indirectly held 8,152 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Company reported first-quarter 2026 Net sales of $5,324 million, up 8.4% from 2025, driven by 1.1% volume growth, 2.2% higher pricing and 5.1% positive foreign exchange. Organic sales grew 2.9%, with Oral, Personal and Home Care organic sales up 3.1% and Hill’s Pet Nutrition up 2.1%.
Gross profit rose to $3,226 million, though gross margin slipped to 60.6% as significantly higher raw and packaging material costs more than offset funding-the-growth savings and pricing. GAAP operating profit fell to $964 million, but on a non-GAAP basis increased 4% to $1,134 million, reflecting restructuring adjustments.
GAAP diluted EPS declined to $0.80 from $0.85, while non-GAAP diluted EPS increased to $0.97 from $0.91, helped by higher operating profit and share count changes. The Board expanded the Strategic Growth and Productivity Program, raising expected cumulative pre-tax charges to $350–$550 million and targeting annualized pre-tax savings of $200–$300 million by the end of 2028.
Colgate-Palmolive Company reported mixed first quarter 2026 results and expanded its Strategic Growth and Productivity Program. Net sales rose to $5,324 million, up 8.4% from $4,911 million, with organic sales up 2.9%. GAAP diluted EPS declined 6% to $0.80, while Base Business diluted EPS increased 7% to $0.97. Operating profit on a GAAP basis fell 10% to $964 million, but Base Business operating profit grew 4% to $1,134 million. Net cash provided by operations was $747 million, producing free cash flow before dividends of $609 million.
The Board approved an expansion of the Strategic Growth and Productivity Program, now expected to generate cumulative pre-tax charges of $350 million to $550 million, up from $200 million to $300 million, with 80% to 90% of these charges in cash and substantially all incurred by December 31, 2028. The program targets organizational changes and supply chain optimization across all regions and businesses. Colgate maintained its 2026 sales and EPS guidance but now expects gross profit margin to be down on both GAAP and Base Business bases.
Colgate-Palmolive Co reports a 13G filing showing 60,404,276 shares beneficially owned (7.52% of the class). The filing states Vanguard Capital Management has sole voting power for 8,184,452 shares and sole dispositive power for 60,404,276 shares.
The filing notes these holdings are reported on behalf of Vanguard-managed funds and accounts under Schedule 13G and were signed on 04/29/2026.
Colgate-Palmolive Company is planning a legal leadership transition. Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, has informed the company of her intention to retire in 2026. On April 8, 2026, the Board elected Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, to become Chief Legal Officer and Secretary effective June 1, 2026. On the same date, the Board elected Ms. Daniels as Vice Chair of the company, also effective June 1, 2026, to support an orderly handover of her responsibilities to Ms. Fishbone.
NORRINGTON LORRIE M reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO director Lorrie M. Norrington received an equity award of 294 shares of Common Stock, valued at $89.05 per share. The award represents a portion of her annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, and increases her direct holdings to 40,160 shares.
Newman Brian reported acquisition or exercise transactions in this Form 4 filing.
Colgate-Palmolive director Brian Newman received 210 shares of Common Stock as a grant on April 1, 2026, at $89.05 per share. The award represents a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 5,534 shares of Colgate-Palmolive Common Stock. In addition, 36 shares are held indirectly through a family trust. This filing reflects routine director compensation rather than an open-market purchase or sale.
Colgate-Palmolive director John P. Bilbrey acquired 266 shares of Common Stock as a compensation award. The shares, valued at $89.05 each, represent a portion of his annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 37,665 Colgate-Palmolive shares and has an additional 4,719 shares held indirectly by a trust. The transaction reflects routine director compensation rather than an open-market purchase.
Colgate-Palmolive Co: The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting 0 shares of Colgate-Palmolive common stock (0%). The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538 (January 12, 1998).